SEPOY.net
No Result
View All Result
Wednesday, June 18, 2025
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

Starting immunotherapy before surgery improves the outlook for patients with stage III-IV melanoma

Nicholas by Nicholas
March 2, 2023
in Health
0
Starting immunotherapy before surgery improves the outlook for patients with stage III-IV melanoma

Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.

READ ALSO

Gut microbiome resists major changes from a nut-rich diet

Grammatical errors could aid in the early detection of schizophrenia

These results, published today in the New England Journal of Medicine, are from a research study led by the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI). The findings originally were presented at a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA6).

The study, known as S1801, was led by Sapna Patel, M.D., chair of the SWOG melanoma committee and associate professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center.

It’s not just what you give, it’s when you give it. The S1801 study demonstrates the same treatment for resectable melanoma given before surgery can generate better outcomes. In this case, we used the immune checkpoint inhibitor pembrolizumab. This treatment relies on the presence of pre-existing T cells coming in contact with cancer cells in the body to generate an immune response, and we found that starting treatment before the melanoma is removed – and with it the bulk of tumor-specific T cells – leads to a greater response than giving it after surgery.”


Sapna Patel, M.D., chair of the SWOG melanoma committee and associate professor of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center

The mechanism of action of immune checkpoint inhibitors such as pembrolizumab is often described as “taking the brakes off” the immune system’s response to tumor cells. The S1801 researchers hypothesized that there would be a larger anti-tumor immune response and longer immunologic memory if pembrolizumab was administered while the melanoma tumor was still in the body as opposed to after that tumor had been removed, when the immune system would be responding primarily to micrometastatic cancer cells.

To test this hypothesis, S1801 investigators enrolled 345 participants with stage IIIB through stage IV melanoma that was deemed operable. Participants ages 18-90 were randomized to receive either upfront surgery followed by 200 mg of pembrolizumab every three weeks (adjuvant-only) for a total of 18 doses, or to 200 mg of pembrolizumab every three weeks for three doses leading up to surgery (neoadjuvant-adjuvant), then an additional 15 doses following surgery.

The primary endpoint measured was the duration of event-free survival, defined as the time from randomization to the occurrence of one of the following: disease progression or toxicity that resulted in not receiving surgery, failure to begin adjuvant therapy within 84 days of surgery, melanoma recurrence after surgery, or death from any cause.

With a median follow-up of 14.7 months, event-free survival was significantly longer in the neoadjuvant-adjuvant therapy arm, with a hazard ratio of 0.58 when compared to the adjuvant therapy arm, which corresponds to a 42% lower event rate in the patients receiving the neoadjuvant regimen.

“Our study noted a significant improvement in event-free survival in the neoadjuvant regimen compared to the adjuvant regimen,” Patel said. “Importantly, a similar number of patients in both arms experienced events before initiating adjuvant pembrolizumab, but the rate of events after initiating adjuvant therapy was higher (worse) in the adjuvant arm.”

The researchers found that the benefit from neoadjuvant therapy was consistent across a range of factors including patient age, sex, performance status, and stage of disease. They also found that the rates of adverse events (side effects) were similar across both arms of the study and that neoadjuvant pembrolizumab did not result in an increase in adverse events related to surgery.

“Based on the findings from S1801, patients with high-risk melanoma should start immunotherapy prior to surgery to generate an immune response while the bulk of the melanoma and the anti-tumor T cells are intact,” Patel said. “Future studies can explore de-escalation strategies for both surgery and adjuvant therapy, as well as approaches for patients whose melanoma does not respond to neoadjuvant therapy.”

Source:

The University of Texas MD Anderson Cancer Center

Journal reference:

Patel, S.P., et al. (2023) Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. New England Journal of Medicine. doi.org/10.1056/NEJMoa2211437.

Tags: Adjuvant TherapyCancerImmune ResponseImmune SystemImmunotherapyMedicineMelanomaOncologyResearchSurgeryTumor

Related Posts

Gut microbiome resists major changes from a nut-rich diet
Health

Gut microbiome resists major changes from a nut-rich diet

June 18, 2025
Grammatical errors could aid in the early detection of schizophrenia
Health

Grammatical errors could aid in the early detection of schizophrenia

June 18, 2025
Global warming fuels an alarming increase in obstructive sleep apnea cases
Health

Global warming fuels an alarming increase in obstructive sleep apnea cases

June 18, 2025
Rare pancreatic cancer patients show remarkable outcomes with immunotherapy
Health

Rare pancreatic cancer patients show remarkable outcomes with immunotherapy

June 17, 2025
Disrupted biological rhythms in teens can produce unexpected brain effects
Health

Disrupted biological rhythms in teens can produce unexpected brain effects

June 17, 2025
Aging family physician workforce challenges primary care in Ontario
Health

Aging family physician workforce challenges primary care in Ontario

June 17, 2025
Next Post
MeToo in Switzerland: No Weinstein, but nothing else?

MeToo in Switzerland: No Weinstein, but nothing else?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: hello@sepoy.net

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • Free Games Winnings bonus slot mystery joker 6000 Free Revolves otherwise Real money Daily T&Cs British
  • Buffalo Revolves The newest Slots Website Win five-hundred Free Gnome slot no deposit bonus Spins
  • fifty 100 percent free Revolves No deposit SA Casinos Summer 2025

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net